These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

289 related items for PubMed ID: 33162516

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.
    Tefferi A.
    Am J Hematol; 2023 May; 98(5):801-821. PubMed ID: 36680511
    [Abstract] [Full Text] [Related]

  • 4. [Clinical application of gene mutation information in myeloproliferative neoplasms].
    Takenaka K.
    Rinsho Ketsueki; 2019 May; 60(6):610-618. PubMed ID: 31281152
    [Abstract] [Full Text] [Related]

  • 5. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
    Tefferi A.
    Am J Hematol; 2021 Jan; 96(1):145-162. PubMed ID: 33197049
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management.
    Tefferi A.
    Am J Hematol; 2018 Dec; 93(12):1551-1560. PubMed ID: 30039550
    [Abstract] [Full Text] [Related]

  • 11. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
    Ahmed RZ, Rashid M, Ahmed N, Nadeem M, Shamsi TS.
    Asian Pac J Cancer Prev; 2016 Dec; 17(3):923-6. PubMed ID: 27039813
    [Abstract] [Full Text] [Related]

  • 12. How I Diagnose Primary Myelofibrosis.
    Prakash S, Orazi A.
    Am J Clin Pathol; 2022 Apr 01; 157(4):518-530. PubMed ID: 35238345
    [Abstract] [Full Text] [Related]

  • 13. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
    Tefferi A.
    Am J Hematol; 2013 Feb 01; 88(2):141-50. PubMed ID: 23349007
    [Abstract] [Full Text] [Related]

  • 14. Presence of triple positive driver mutations in JAK2, CALR and MPL in primary myelofibrosis: a case report and literature review.
    Zhao L, Zhang H, Chen J, Ma H, Liu B.
    Hematology; 2024 Dec 01; 29(1):2402106. PubMed ID: 39268974
    [Abstract] [Full Text] [Related]

  • 15. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A.
    Am J Hematol; 2016 Dec 01; 91(12):1262-1271. PubMed ID: 27870387
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications.
    Ross DM, Babon JJ, Tvorogov D, Thomas D.
    Haematologica; 2021 May 01; 106(5):1244-1253. PubMed ID: 33472356
    [Abstract] [Full Text] [Related]

  • 18. The Genetic Basis of Primary Myelofibrosis and Its Clinical Relevance.
    Rumi E, Trotti C, Vanni D, Casetti IC, Pietra D, Sant'Antonio E.
    Int J Mol Sci; 2020 Nov 24; 21(23):. PubMed ID: 33255170
    [Abstract] [Full Text] [Related]

  • 19. Immunoblotting-assisted assessment of JAK/STAT and PI3K/Akt/mTOR signaling in myeloproliferative neoplasms CD34+ stem cells.
    Calabresi L, Balliu M, Bartalucci N.
    Methods Cell Biol; 2022 Nov 24; 171():81-109. PubMed ID: 35953207
    [Abstract] [Full Text] [Related]

  • 20. Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities.
    Coltro G, Loscocco GG, Vannucchi AM.
    Int Rev Cell Mol Biol; 2021 Nov 24; 365():1-69. PubMed ID: 34756241
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.